Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Medical Genetics · Ehlers-Danlos Syndrome

When Is Genetic Testing Recommended for Suspected EDS?

At a Glance

Routine genetic testing is not used to diagnose common hEDS or HSD because no validated single genetic test exists. A genetics referral is recommended when vascular events, severe tissue fragility, unusual eye or skeletal findings, or a concerning family history suggest another inherited disorder.

If you suspect you have hypermobile Ehlers-Danlos Syndrome (hEDS) or Hypermobility Spectrum Disorder (HSD), genetic testing is not a routine part of the initial diagnosis. Because no single causative gene or validated clinical genetic test has been established for the common hEDS phenotype, these conditions are diagnosed clinically through a physical exam and medical history [1][2].

However, your doctor may recommend a genetics referral if your symptoms or family history include “red flags” that point to a different, potentially more dangerous inherited connective tissue disorder [1][3]. While you wait for a genetic evaluation, treatment for your hEDS/HSD symptoms (like joint instability or pain) should not be put on hold.

⚠️ Emergency Warning
If you experience sudden and severe chest, back, or abdominal pain, a “tearing” sensation, unexplained fainting, signs of a stroke, severe shortness of breath, or unexplained internal bleeding, seek emergency medical care immediately. These can be signs of a life-threatening vascular event and require an emergency room, not a routine genetics referral [4].

Red Flags That Prompt a Genetics Referral

Mildly stretchy skin or typical scars are common in hEDS and HSD. However, a referral to a genetics professional is important if you or your close relatives have experienced a combination of more severe or unusual features [4][5]. A doctor will look for patterns including:

  • Vascular or organ emergencies: A history of arterial aneurysm (bulging blood vessels), arterial dissection (tearing), or the rupture of an artery, bowel, or uterus [4].
  • Family history of sudden events: A family history of sudden, unexplained early death, or early arterial events [6][5].
  • Severe skin or tissue fragility: Extremely fragile, easily torn skin, pronounced hyperextensibility (very stretchy skin), or wide, sunken scars (atrophic scarring) [7][4].
  • Unusual facial or eye features: Unusually widely spaced eyes (hypertelorism), a split in the tissue at the back of the throat (bifid uvula), a cleft palate, or dislocation of the lens in the eye (ectopia lentis) [5].
  • Severe skeletal or bone issues: Significant bone fragility leading to multiple low-impact fractures, a blue tint to the whites of the eyes (blue sclerae), congenital hip dislocation, or unusually severe spine curvature (scoliosis) [8][9][5].

Having one of these features does not automatically mean you have a life-threatening disorder, but it does mean a deeper evaluation is warranted.

The Genetics Evaluation: What to Expect

Depending on your healthcare system, you may see a medical geneticist (a physician specializing in genetics) or a genetic counselor. To get the most out of your appointment, come prepared: bring records of any aneurysms, fractures, or unusual surgeries; gather the ages and causes of any vascular events or sudden deaths in your family; and bring reports from past imaging [1].

A genetic evaluation is more than just a blood or saliva test. The clinician will take a detailed three-generation family history and perform a physical exam. Sometimes, they may recommend other clinical evaluations before or instead of genetic testing, such as an echocardiogram (an ultrasound of the heart to check for aortic enlargement) or a specialized eye exam [10][5].

How Targeted Testing Works

There is no single standard “connective tissue test.” If testing is appropriate, the geneticist will choose a specific single-gene test or a customized multi-gene panel based on your unique features. Common examples of what these panels look for include:

  • Vascular EDS (vEDS): Often checks the COL3A1 gene [11].
  • Classical EDS (cEDS): Evaluates COL5A1 and COL5A2 genes [11].
  • Marfan Syndrome: Checks the FBN1 gene [5].
  • Loeys-Dietz Syndrome: Looks for mutations in several genes, including TGFBR1/2 and SMAD2/3 [5].
  • Osteogenesis Imperfecta (Brittle Bone Disease): Frequently evaluates COL1A1 and COL1A2 genes, though other genes can also be involved [9].

Understanding Your Genetic Test Results

Interpreting a genetic test requires clinical expertise, as the results are rarely a simple “yes or no.”

If the test is negative:
A negative result means no reportable mutations were found in the specific genes and variant types the laboratory tested. This reduces the likelihood that you have conditions like vascular EDS or Marfan syndrome, but it does not completely eliminate the possibility, as some variants can be technically missed or some disease-causing genes are not yet known [1].

A negative panel also does not confirm you have hEDS or HSD. hEDS requires a doctor to actively evaluate you using the strict 2017 international clinical criteria (which check for generalized joint hypermobility, specific physical traits, and the exclusion of other disorders) [2]. HSD is a clinical diagnosis used when you have symptomatic joint hypermobility but do not meet the full hEDS criteria [2]. If your test is negative, but you still meet all the clinical requirements based on your physical exam and history, your diagnosis of hEDS or HSD remains the most accurate label [12].

If you have a Variant of Uncertain Significance (VUS):
It is very common to find a VUS—a genetic change that scientists do not yet fully understand [13]. A VUS is not a diagnosis. It should not be used to confirm a disorder, and it should not change your medical care, screening routines, or decisions about family planning [13]. Your genetics team may reclassify it in the future as more research becomes available, so it is simply a finding to file away for now.

Common questions in this guide

Do people with hEDS or HSD routinely need genetic testing?
No. Common hEDS and HSD are usually diagnosed from medical history and physical examination because no validated genetic test identifies the common hEDS pattern. A genetics referral may still be appropriate when red flags suggest another inherited connective-tissue disorder.
Which findings should prompt a genetics referral for EDS?
Referral is especially important when there is a history of arterial aneurysm, dissection, or rupture; severe skin fragility or unusual scarring; lens dislocation or certain palate or facial features; major bone fragility; or a family history of sudden unexplained early death or early arterial events. One finding alone does not prove a dangerous disorder, but a clinician should assess the overall pattern.
What happens during a genetics evaluation for suspected EDS?
A medical geneticist or genetic counselor typically reviews a detailed three-generation family history, performs a physical examination, and examines records such as imaging, fracture reports, or surgical notes. Depending on your findings, the team may recommend an echocardiogram or a specialized eye exam before deciding whether targeted genetic testing is useful.
What genes might be included in testing for an EDS-like condition?
The genes depend on your features rather than a single standard connective-tissue test. Examples include COL3A1 for vascular EDS, COL5A1 and COL5A2 for classical EDS, FBN1 for Marfan syndrome, TGFBR1, TGFBR2, SMAD2, or SMAD3 for Loeys-Dietz syndrome, and COL1A1 or COL1A2 for osteogenesis imperfecta.
What does a negative genetic test mean if I may have hEDS or HSD?
It means the laboratory did not find a reportable change in the genes and types of genetic changes it examined. This can make some inherited conditions less likely but cannot rule them out completely, and it does not by itself confirm or exclude hEDS or HSD. Those diagnoses still depend on clinical evaluation, including the 2017 hEDS criteria.
Does a variant of uncertain significance diagnose EDS?
No. A variant of uncertain significance is a genetic change whose meaning is not yet clear, so it should not be used to diagnose EDS or to change treatment, screening, or family-planning decisions on its own. The genetics team may revisit the result if scientific evidence changes.
When should possible EDS symptoms be treated as an emergency?
Seek emergency care for sudden severe chest, back, or abdominal pain; a tearing sensation; unexplained fainting; stroke symptoms; severe shortness of breath; or unexplained internal bleeding. These symptoms can signal a life-threatening vascular event and should not wait for a routine genetics appointment.

Get notified when new evidence is published on hypermobility syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Hypermobile Ehlers Danlos for the Primary Care Provider.

    White L, Procknow SS

    Missouri medicine 2024; (121(4)):289-296.

    PMID: 39575079
  2. 2

    Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.

    Yew KS, Kamps-Schmitt KA, Borge R

    American family physician 2021; (103(8)):481-492.

    PMID: 33856167
  3. 3

    The 2017 international classification of the Ehlers-Danlos syndromes.

    Malfait F, Francomano C, Byers P, et al.

    American journal of medical genetics. Part C, Seminars in medical genetics 2017; (175(1)):8-26 doi:10.1002/ajmg.c.31552.

    PMID: 28306229
  4. 4

    Ehlers-Danlos Syndromes and Related Disorders: Diagnostic Challenges and the Need for an Interdisciplinary Patient Care in Germany.

    Kernich N, Peters F, Schreml J, et al.

    Dermatology (Basel, Switzerland) 2025; (241(2)):124-132 doi:10.1159/000542026.

    PMID: 39657610
  5. 5

    Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome.

    Meester JAN, Verstraeten A, Schepers D, et al.

    Annals of cardiothoracic surgery 2017; (6(6)):582-594 doi:10.21037/acs.2017.11.03.

    PMID: 29270370
  6. 6

    Cardiogenetics: genetic testing in the diagnosis and management of patients with aortic disease.

    Thakker PD, Braverman AC

    Heart (British Cardiac Society) 2021; (107(8)):619-626 doi:10.1136/heartjnl-2020-317036.

    PMID: 33334864
  7. 7

    Multisystemic manifestations in a cohort of 75 classical Ehlers-Danlos syndrome patients: natural history and nosological perspectives.

    Ritelli M, Venturini M, Cinquina V, et al.

    Orphanet journal of rare diseases 2020; (15(1)):197 doi:10.1186/s13023-020-01470-0.

    PMID: 32736638
  8. 8

    Diagnostic outcomes for molecular genetic testing in children with suspected Ehlers-Danlos syndrome.

    Damseh N, Dupuis L, O'Connor C, et al.

    American journal of medical genetics. Part A 2022; (188(5)):1376-1383 doi:10.1002/ajmg.a.62672.

    PMID: 35128800
  9. 9

    Clinical and molecular features of patients with COL1-related disorders: Implications for the wider spectrum and the risk of vascular complications.

    Takeda R, Yamaguchi T, Hayashi S, et al.

    American journal of medical genetics. Part A 2022; (188(9)):2560-2575 doi:10.1002/ajmg.a.62887.

    PMID: 35822426
  10. 10

    Cardiovascular manifestations of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.

    Rashed ER, Ruiz Maya T, Black J, et al.

    Vascular medicine (London, England) 2022; (27(3)):283-289 doi:10.1177/1358863X211067566.

    PMID: 35000503
  11. 11

    The dysmorphic phenotype in vascular Ehlers Danlos syndrome.

    Lyness JR, Morrison PJ

    Clinical dysmorphology 2023; (32(1)):1-6 doi:10.1097/MCD.0000000000000437.

    PMID: 36503916
  12. 12

    Differential diagnosis and diagnostic flow chart of joint hypermobility syndrome/ehlers-danlos syndrome hypermobility type compared to other heritable connective tissue disorders.

    Colombi M, Dordoni C, Chiarelli N, Ritelli M

    American journal of medical genetics. Part C, Seminars in medical genetics 2015; (169C(1)):6-22 doi:10.1002/ajmg.c.31429.

    PMID: 25821090
  13. 13

    Targeted next-generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome.

    Weerakkody RA, Vandrovcova J, Kanonidou C, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2016; (18(11)):1119-1127 doi:10.1038/gim.2016.14.

    PMID: 27011056

This page is for informational purposes only and does not constitute medical advice. A clinician or genetics professional should assess your personal and family history, interpret test results, and advise you about urgent symptoms.